MEI Pharma Valuation
Is MEIP undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Key Valuation Metric
Which metric is best to use when looking at relative valuation for MEIP?
Other financial metrics that can be useful for relative valuation.
| What is MEIP's n/a Ratio? | |
|---|---|
| n/a Ratio | 0x |
| n/a | n/a |
| Market Cap | US$30.50m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | n/a |
| Enterprise Value/EBITDA | n/a |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does MEIP's PS Ratio compare to its peers?
| Company | PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 20.2x | ||
SLS SELLAS Life Sciences Group | 40.5x | 60.1% | US$40.5m |
ATHX Athersys | 3.7x | -86.0% | US$22.1m |
AVTX Avalo Therapeutics | 1.3x | 39.1% | US$23.1m |
ABEO Abeona Therapeutics | 35.3x | 52.8% | US$49.9m |
MEIP MEI Pharma | 0.5x | -7.1% | US$30.5m |
Price to Earnings Ratio vs Industry
How does MEIP's PE Ratio compare vs other companies in the US Biotechs Industry?
Price to Sales Ratio vs Fair Ratio
What is MEIP's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 0.5x |
| Fair PS Ratio | 1.8x |
Price-To-Sales vs Fair Ratio: MEIP is good value based on its Price-To-Sales Ratio (0.5x) compared to the estimated Fair Price-To-Sales Ratio (1.8x).
Share Price vs Fair Value
What is the Fair Price of MEIP when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | US$0.23 | US$1.65 +620.8% | 92.8% | US$4.00 | US$0.10 | n/a | 4 |
| Mar ’24 | US$0.22 | US$1.72 +687.5% | 80.0% | US$4.00 | US$0.10 | n/a | 5 |
| Feb ’24 | US$0.31 | US$2.57 +733.3% | 58.7% | US$5.00 | US$0.40 | n/a | 6 |
| Jan ’24 | US$0.24 | US$2.90 +1,090.5% | 67.1% | US$6.00 | US$0.40 | n/a | 6 |
| Dec ’23 | US$0.33 | US$5.40 +1,551.4% | 91.7% | US$15.00 | US$0.40 | n/a | 6 |
| Nov ’23 | US$0.35 | US$5.21 +1,373.0% | 87.6% | US$15.00 | US$0.50 | n/a | 7 |
| Oct ’23 | US$0.39 | US$4.81 +1,144.8% | 91.5% | US$15.00 | US$0.50 | n/a | 8 |
| Sep ’23 | US$0.50 | US$4.81 +853.7% | 91.5% | US$15.00 | US$0.50 | n/a | 8 |
| Aug ’23 | US$0.48 | US$4.81 +904.7% | 91.5% | US$15.00 | US$0.50 | n/a | 8 |
| Jul ’23 | US$0.58 | US$4.81 +729.7% | 91.5% | US$15.00 | US$0.50 | n/a | 8 |
| Jun ’23 | US$0.46 | US$5.15 +1,024.2% | 78.6% | US$15.00 | US$0.50 | n/a | 10 |
| May ’23 | US$0.49 | US$5.30 +978.3% | 74.5% | US$15.00 | US$1.00 | n/a | 10 |
| Apr ’23 | US$0.59 | US$5.70 +864.3% | 71.9% | US$15.00 | US$1.00 | US$0.23 | 10 |
| Mar ’23 | US$2.07 | US$9.90 +378.3% | 41.8% | US$20.00 | US$4.00 | US$0.22 | 10 |
| Feb ’23 | US$1.93 | US$10.89 +464.2% | 33.1% | US$20.00 | US$7.00 | US$0.31 | 9 |
| Jan ’23 | US$2.67 | US$10.56 +295.3% | 26.5% | US$17.00 | US$7.00 | US$0.24 | 9 |
| Dec ’22 | US$3.03 | US$10.89 +260.0% | 33.1% | US$20.00 | US$7.00 | US$0.33 | 9 |
| Nov ’22 | US$2.85 | US$10.67 +274.3% | 34.2% | US$20.00 | US$7.00 | US$0.35 | 9 |
| Oct ’22 | US$2.63 | US$10.67 +305.6% | 34.2% | US$20.00 | US$7.00 | US$0.39 | 9 |
| Sep ’22 | US$2.83 | US$10.06 +255.3% | 17.3% | US$13.00 | US$7.00 | US$0.50 | 9 |
| Aug ’22 | US$2.70 | US$10.06 +272.4% | 17.3% | US$13.00 | US$7.00 | US$0.48 | 9 |
| Jul ’22 | US$2.95 | US$9.67 +227.7% | 23.3% | US$13.00 | US$5.50 | US$0.58 | 9 |
| Jun ’22 | US$3.02 | US$9.67 +220.1% | 23.3% | US$13.00 | US$5.50 | US$0.46 | 9 |
| May ’22 | US$3.65 | US$9.67 +164.8% | 23.3% | US$13.00 | US$5.50 | US$0.49 | 9 |
| Apr ’22 | US$3.39 | US$9.67 +185.2% | 23.3% | US$13.00 | US$5.50 | US$0.59 | 9 |